Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - PRTO, ROAN, PGNX

TARA

NEW YORK, NY / ACCESSWIRE / October 18, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

Proteon Therapeutics, Inc. (NASDAQ:PRTO)

The investigation concerns whether Proteon and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed merger between Proteon and ArTara Therapeutics, Inc. in an all-stock transaction. If you are a Proteon shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/proteon-therapeutics-inc-prto-stock-merger-artara-therapeutics/.

Roan Resources, Inc. (NYSE:ROAN)

The investigation concerns whether Roan and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Roan to Citizen Energy Operating, LLC for $1.52 per share. If you are a Roan shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/roan-resources-inc-stock-merger-citizen-energy/.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

The investigation concerns whether Progenics and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Progenics to Lantheus Holdings, Inc. for 0.2502 shares of Lantheus stock for each share of Progenics stock. If you are a Progenics shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/progenics-pharmaceuticals-inc-pgnx-stock-merger-lantheus/.

On behalf of shareholders of these companies, Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060|
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

SOURCE: Halper Sadeh LLP



View source version on accesswire.com:
https://www.accesswire.com/563476/SHAREHOLDER-INVESTIGATION-ALERT-Halper-Sadeh-LLP-Continues-to-Investigate-Whether-the-Sale-of-These-Companies-is-Fair-to-Shareholders--PRTO-ROAN-PGNX